logo

LFSC

ยทNASDAQ
--
--(--)
--
--(--)
Key Stats
Assets Under Management
98.64MUSD
Fund Flows (1Y)
11.12MUSD
Dividend Yield
--
Discount/Premium to NAV
-0.01%
Shares Outstanding
2.50M
Expense Ratio
0.79%
About F/m Emerald Life Sciences Innovation ETF
Issuer
F/m Investments LLC
Brand
F/m
Inception Date
Oct 30, 2024
Structure
Open-Ended Fund
Index Tracked
--
Management Style
Active
Dividend Treatment
Distributes
Distribution Tax Treatment
Qualified dividends
Income Tax Type
Capital Gains
Max ST Capital Gains Rate
39.60%
Max LT Capital Gains Rate
20.00%
Primary Advisor
F/m Investments LLC
Distributor
Quasar Distributors LLC
LFSC seeks to invest in innovative life sciences companies that are expected to create value and long-term growth. The actively managed fund relies on a specialized and experienced team to research complex life sciences companies. It invests in US equity securities identified to have growth potential that meet the criteria of technological advancement, market disruption, or artificial intelligence. The broad life science field includes biotechnology, pharmaceutical, medical diagnostics and devices, healthcare services and technologies, and synthetic biology. Stock selection employs an extensive 10-step research process that includes reviews of publicly available and third-party information, peer reviews, financial and valuation models, internal research, surveys, as well as interviews and contact with management, industry and medical professionals, supply chain, and collaboration within the investment team. The fund may invest up to 20% in foreign companies listed on a US exchange.
Classification
Asset Class
Equity
Category
Sector
Focus
Health Care
Niche
Pharma, Biotech & Life Sciences
Strategy
Active
Geography
--
Weighting Scheme
Proprietary
Selection Criteria
Proprietary
Returns
1-Month
3-Month
YTD
1-Year
3-Year
5-Year
Price Performance
+1.18%+28.41%+60.37%+62.70%+52.17%+52.17%
NAV Total Return
+13.72%+30.34%+61.51%+61.59%-0.05%-0.05%
Ratings

No data is currently available

Ainvestโ€™s AI-powered ETF Scoring Algorithm, built to help retail investors make smarter, data-driven decisions. Leveraging deep learning, reinforcement learning, and large language models, the algorithm scores ETFs across five key dimensions: Fund Flow, Momentum, Safety, Fundamentals, and Performance. Each factor is weighted by its correlation to future returns, resulting in a single, actionable score. Backtested over five years with consistently strong predictive accuracy. Ainvest brings institutional-grade artificial intelligence to everyday investorsโ€”transforming complexity into clarity with every score.
Holdings Analysis

Sector

Healthcare

100.00%

Asset

Region

97.24%
2.76%

Category

Ratio

North America

97.24%

Asia

2.76%

Investment Style

No data is currently available

Top 10 Holdings

Symbol

Ratio

logo

Cogent Biosciences Inc

8.48%
logo

WaVe Life Sciences Ltd

6.20%
logo

LivaNova PLC

6.14%
logo

Travere Therapeutics Inc

5.77%
logo

Corcept Therapeutics Inc

5.04%
logo

Guardant Health Inc

4.87%
logo

TransMedics Group Inc

4.21%
logo

Bridgebio Pharma Inc

4.11%
logo

Savara Inc

4.05%
logo

Mirum Pharmaceuticals Inc

3.89%

Top 10 Weight 52.76%

39 Total Holdings

Dividends

No data is currently available

Premium/Discount Chart
Premium/Discount to NAV
Price
Assets Under Management
Assets Under Management
Fund Flows
Inflows
Outflows